Table 4.
Efficacy simulation of MTOI solutions in AAnetwork
| [I]/Ki |
Inhibition of PGE2 (%) | Inhibition of LTB4 (%) | [PGI2]/[TXA2] | ||||||
|---|---|---|---|---|---|---|---|---|---|
| PLA2 | COX-2 | PGES | 5-LOX | LTA4H | COX-1 | ||||
| Control | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.6817 |
| 1 | 0 | 400 | 0 | 0 | 100 | 56.5 | 97 | 97 | 0.6843 |
| 2 | 14 | 80 | 0 | 0 | 50 | 35 | 97 | 97 | 0.6857 |
| 3 | 12 | 60 | 0 | 60 | 40 | 13 | 97 | 97 | 0.6855 |
| 4 | 9 | 20 | 10 | 50 | 30 | 26 | 97 | 97 | 0.6823 |
| 5 | 0 | 0 | 20 000 | 0 | 45 | 0 | 97 | 95 | 0.5405 |
| 6 | 0 | 200 | 50 | 0 | 45 | 26.5 | 97 | 95 | 0.6853 |
| 7 | 0 | 200 | 50 | 60 | 30 | 32.5 | 97 | 95 | 0.6833 |
| 8 | 0 | 450 | 0 | 1200 | 0 | 95 | 97 | 97 | 0.6819 |
| 9 | 0 | 450 | 0 | 80 | 50 | 79 | 97 | 97 | 0.6817 |
| 10 | 0 | 200 | 50 | 1200 | 0 | 40.5 | 97 | 97 | 0.6824 |
| 11 | 250 | 5000 | 0 | 0 | 0 | 5000 | 98 | 95 | 0.6255 |
| 12 | 250 | 5000 | 5000 | 0 | 0 | 5000 | 98 | 95 | 0.625 |
| 13 | 15 | 190 | 0 | 90 | 0 | 190 | 98 | 95 | 0.6837 |
| 14 | 15 | 190 | 190 | 90 | 0 | 190 | 98 | 95 | 0.6832 |
| 15 | 15 | 105 | 105 | 0 | 25 | 105 | 98 | 95 | 0.6835 |
The same parameter set used is the same as in Figure 3. In the same way, the ratio of PGI2/TXA2 reflects possible side effects of the drug. After taking the medicine, if PGI2/TXA2 becomes much greater than the normal level, bleeding side effects may occur. If PGI2/TXA2 decreases significantly, cardiovascular risks will be raised.